SMS Lifesciences India Limited

NSE SMSLIFE.NS

SMS Lifesciences India Limited EBITDA Margin for the year ending March 31, 2024: 11.42%

SMS Lifesciences India Limited EBITDA Margin is 11.42% for the year ending March 31, 2024, a 5.45% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

SMS Lifesciences India Limited EBITDA Margin for the year ending March 31, 2023 was 10.83%, a -23.10% change year over year.
SMS Lifesciences India Limited EBITDA Margin for the year ending March 31, 2022 was 14.08%, a 13.45% change year over year.
SMS Lifesciences India Limited EBITDA Margin for the year ending March 31, 2021 was 12.41%, a 15.14% change year over year.
SMS Lifesciences India Limited EBITDA Margin for the year ending March 31, 2020 was 10.78%, a 7.98% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NSE: SMSLIFE.NS

SMS Lifesciences India Limited

CEO	Mr. Talluri Veera Venkata Satyanarayana Murthy
IPO Date	Aug. 18, 2017
Location	India
Headquarters	Plot No. 19-III
Employees	574
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Perfumes & Fragrances Personal Care Plastics

Description

SMS Lifesciences India Limited manufactures, buys, imports, and sells active pharmaceutical ingredients (API) and its intermediates, organic and inorganic chemicals, and pharmaceuticals in India. The company offers APIs in various therapeutic areas, such as antiulcer, antifungal, and erectile dysfunction. It also provides consultancy services. The company exports its products. The company was founded in 1990 and is based in Hyderabad, India.

Key trends

Past 5 years